OSIRIS THERAPEUTICS,INC. (NASDAQ:OSIR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

OSIRIS THERAPEUTICS,INC. (NASDAQ:OSIR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

Appointment of Independent Directors

On February 7, 2017, the Board appointed Messrs. Uwe Sommer and Thomas J. Knapp as independent directors. Messrs. Sommer and Knapp will stand for re-election at the 2017 Annual Meeting of Stockholders. Mr. Sommer and Mr. Knapp have been appointed to serve as members of the Nominating Committee and the Compensation Committee. Each of Mr. Sommer and Mr. Knapp will be entitled to receive the compensation received by Board members under the Company’s standard compensation policy and practices.

There is no arrangement or understanding between either Mr. Sommer or Mr. Knapp and any other person to which either was selected as a director. Neither Mr. Sommer nor Mr. Knapp has any direct or indirect material interest in any transaction required to be disclosed to Item 404(a) of Regulation S-K.

A copy of the press release issued by the Company to announce the appointment Mr. Sommer and Mr. Knapp to the Board is included as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.



About OSIRIS THERAPEUTICS, INC. (NASDAQ:OSIR)

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

OSIRIS THERAPEUTICS, INC. (NASDAQ:OSIR) Recent Trading Information

OSIRIS THERAPEUTICS, INC. (NASDAQ:OSIR) closed its last trading session up +0.02 at 5.94 with 69,696 shares trading hands.

An ad to help with our costs